PHYTOMENADIONE (vitamin K1), 10mg/ml, 1ml, amp.
STD
DORAPHYT1A1
Valid Article
Account code:
60000
HS Code:
300490
Last Updated on:
22/10/2024, 15:28:33
Former
Code(s):
-X
10.2 - Medicines affecting coagulation
Classification of the medicines in groups and subgroups according to their therapeutic use.
The classification used by MSF is based on the WHO Model List of Essential Medicines.
B02BA01
Anatomical Therapeutic Chemical Classification according to WHOCC
OC subscriptions: included in supply or field order tools (e.g. UniField)
|
|
SC subscriptions: included in supply or field tools
|
|
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
|
|
PHYTOMENADIONE (vitamin K1)
Therapeutic Action
Vitamin K, anti-haemorrhagic
Indications
Prophylaxis and treatment of haemorrhagic disease of the newborn
Instructions for use
Two presentations of phytomenadione are available for different indications:
- Oral: 10mg/ml solution in 1ml ampoule. It is recommended to give vitamin K1 (10 mg/day PO) to pregnant women on rifampicin treatment during the last two weeks of pregnancy to prevent haemorrhagic disease of the newborn.
- Injectable: 10mg/ml solution in 0.2 ml ampoule (= 2 mg/amp). Indicated for the prevention and treatment of haemorrhagic disease of the newborn.
Both presentations are mixed micelles solutions and are supplied with an oral dosing syringe.
Mixed micelles are composed of glycocholic acid (bile acid) and lecithin in an aqueous solution allowing solubilization of the vitamin K and, therefore, an oral absorption equivalent to that by injectable route.
For this reason, both presentations can be administered either by ORAL or INJECTABLE route.
Storage
Below 25°C - Protect from sunlight